Daily treatment with Fycompa (perampanel), on top of standard medications, was safe and reduced seizure frequency for children with…
Articles by Lindsey Shapiro, PhD
Add-on treatment with Diacomit (stiripentol) was associated with reductions in the number of episodes of status epilepticus (SE),…
Two-thirds of 24 children and young adults with Dravet syndrome experienced clinically meaningful declines in seizure frequency after adding…
Add-on therapies Diacomit (stiripentol) and Fintepla (fenfluramine) were found to be more effective for seizure control in…
The severity of seizures was reduced among Dravet syndrome patients in the U.K. over 10 years, but developmental outcomes…
Treatment with the investigational therapy STK-001 led to significant reductions in seizure frequency and clinically meaningful improvements in cognition…
Fycompa (perampanel) was found to safely reduce seizure frequency among patients with genetic forms of epilepsy, including Dravet…
A molecule designed to enhance activity at certain GABA-A receptor proteins in the brain protected against seizures and eased anxiety…
Behavioral development in children and teens with Dravet syndrome generally held stable in the first year of an observational…
Real-world use of Fintepla (fenfluramine) was found to be safe and effective for people with Dravet syndrome (DS)…